Approved for ENFLONSIA is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.. ENFLONSIA is a monoclonal antibody with anti-RSV activity [see Microbiology (12.4) ]. Side effects, costs, interactions, manufacturer, and generic alternatives sourced from FDA labels, openFDA…
Loading full data from Know Your Drugs Institute…